Post-remission therapy for acute myeloid leukemia.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) treatment relies on intensive post-remission therapies like chemotherapy and hematopoietic stem cell transplantation (HSCT).
• Recent advances include maintenance therapy with novel agents and a deeper understanding of AML genetics influencing classification and risk stratification.
• Minimal residual disease (MRD) assessment is crucial for dynamic treatment adjustments.

Purpose of the Study:

• To review current and emerging treatment strategies for acute myeloid leukemia.
• To highlight the role of genetic profiling and MRD assessment in tailoring therapy.
• To discuss the evolving landscape of AML treatment towards genotype-adapted approaches.

Main Methods:

• Review of current clinical practices and recent clinical trial data in AML treatment.
• Analysis of the impact of genetic mutations on disease classification and risk stratification.
• Evaluation of the utility of minimal residual disease monitoring in guiding treatment decisions.

Main Results:

• Allogeneic HSCT remains a standard for high-risk AML, while autologous HSCT shows promise in low-risk patients.
• Maintenance therapies with kinase inhibitors and demethylating agents are under investigation.
• Genotype-specific treatments are emerging as a potential future direction, moving beyond traditional risk-based strategies.

Conclusions:

• AML treatment is advancing with personalized approaches based on genetic profiles and MRD status.
• Novel maintenance therapies and targeted agents are expanding treatment options.
• The future of AML therapy likely involves more genotype-driven, individualized treatment strategies.